Skip to main content
. 2021 Jul 29;12:696170. doi: 10.3389/fpsyt.2021.696170

Figure 1.

Figure 1

Overview of the study design. Both patients and controls completed a pre-phase (“baseline”) of 6 days, with a portable ECG recording during the first 4 days. Only patients proceeded to a treatment with either ketamine (66%) or placebo (33%) and a subsequent follow-up phase of 6 days (out of which 4 days with psychophysiological recording). Responder status was assessed 24 h post-ketamine administration.